MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: This study aimed to explore the efficacy of opicapone (OPC) 50 mg versus an extra 100 mg levodopa (L-dopa) dose to treat early wearing-off…
  • 2024 International Congress

    Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support

    M. Soileau, J. Bronstein, L. Harmer, M. Shah, R. Gupta, L. Verhagen Metman (Georgetown, USA)

    Objective: To assess the efficacy and safety of foslevodopa/foscarbidopa (LDp/CDp) in people with Parkinson’s (PwP) with and without care partner support. Background: The progression of…
  • 2024 International Congress

    WATCH-PD2: A Remote Extension Digital Measures Study in Early Parkinson’s Disease: Study Design and Status Update

    J. Adams, A. Lerner, R. Al-Rubayie, T. Kangarloo, Y. Gong, V. Khachadourian, B. Tracey, D. Volfson, R. Lazman, J. Cosman, J. Edgerton, D. Anderson, A. Best, M. Kostrzebski, P. Auinger, C. Tarolli, M. Müller, D. Stephenson, E. Dorsey (Rochester, USA)

    Objective: To evaluate longitudinal change in WATCH-PD digital measures in a remote extension study in order to maximize learnings and inform use of digital measures…
  • 2024 International Congress

    Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies

    R. Petty, V. Agarwal, J. Allison, S. Bartolomeu Pires, M. Bartlett, T. Boey, R. Croucher, H. Collins, S. Collins, E. Davies, J. Duffen, R. Ellis-Doyle, C. Gonzalez-Robles, F. Hudson, J. Inches, L. Miller, G. Mills, S. Wonnacott, T. Foltynie, C. Carroll, S. Mullin, M. Zeissler (Plymouth, United Kingdom)

    Objective: To understand successful recruitment and retention strategies for clinical research studies in Parkinson’s disease (PD) Background: Half of all clinical trials do not reach…
  • 2024 International Congress

    Preliminary Efficacy of Bilateral Intraputaminal Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 18-Month Follow-Up From a Phase 1b Study

    N. Phielipp, C. Christine, A. Merola, J. Elder, P. Larson, W. San Sebastian, M. Fiandaca, C. Urrea, M. Wisniewski, A. van Laar, A. Kells, K. Bankiewicz (Irvine, USA)

    Objective: To assess the preliminary efficacy of bilateral intraputaminal delivery of adeno-associated virus serotype 2 containing glial cell line–derived neurotrophic factor (AAV2-GDNF; AB-1005) for patients…
  • 2024 International Congress

    The Effects of Baduanjin on Fine Motor Skills in Mild and Moderate Parkinson’s Disease

    JUN. Li, KF. Li, HZ. Chen, WM. Yang (Hefei, China)

    Objective: To investigate whether Baduanjin Qigong exercise could help improve fine motor skills in patients with Parkinson's disease. Background: It is common for people with…
  • 2024 International Congress

    Slow-SPEED-NL: study protocol for a remote trial of exercise for Parkinson’s disease prevention

    T. Oosterhof, E. Mitchell, A. Ascherio, B. Bloem, K. van Dijk, B. Dijkstra, L. Kaufmann, R. Lathey, E. Macklin, A. Navangul, A. Pijpers, H. Rowbotham, R. Schneider, M. Schwarzschild, N. de Vries, A. Noyce, S. Darweesh (Nijmegen, Netherlands)

    Objective: To determine the feasibility and preliminary efficacy of a remote exercise intervention in prodromal Parkinson’s disease (PD). Background: Disease-slowing interventions have been ineffective in…
  • 2024 International Congress

    The challenge to prevent Parkinson’s Disease with a new in vitro approach

    C. Dalla Verde, S. Gazzin, C. Tiribelli (Trieste, Italy)

    Objective: This research line aims to perform a compound screening on the prophylactic capacity of a high number of nutraceuticals and drugs to prevent dopaminergic…
  • 2024 International Congress

    Beta peaks as predictor for DBS outcome in Parkinson’s disease

    V. Molinari, M. Sure, E. Florin, C. Hartmann, A. Schnitzler (Düsseldorf, Germany)

    Objective: Determining the relevance of subthalamic (STN) beta peaks in Parkinson's disease (PD) patients with deep brain stimulation (DBS) in relation to the best possible…
  • 2024 International Congress

    Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use

    D. Santos Garcia, W. Jost, M. José Martí, M. Fonseca, C. Denecke Muhr, I. Pijuan (A Coruña, Spain)

    Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…
  • « Previous Page
  • 1
  • …
  • 114
  • 115
  • 116
  • 117
  • 118
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley